The Harvard College Alzheimer’s Buddies (HCAB) student association is organizing an interdisciplinary symposium to encourage discussion and debate among students on the complexity of Alzheimer’s disease. The Alzheimer’s Symposium, which is open not only for students, but for anyone interested in participating, is taking place on April 18th in Cambridge, MA. The…
News
Evidence indicates that low-frequency alternating magnetic fields generated by overhead power lines aggravate neurodegenerative disorders including Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). Nevertheless, recent research conducted by scientists from the Institute of Pathobiochemistry at the Medical Center of Johannes Gutenberg University Mainz (JGU) in Germany found no evidence…
A new study led by a team of researchers at the Icahn School of Medicine at Mount Sinai Hospital in New York recently revealed that compounds called glycotoxins found in over-cooked foods may increase the risk for age-related dementia, with Alzheimer’s disease the most common type of dementia. The study is…
Dr. Anuradha Kalani from the University of Louisville in Kentucky and colleagues recently presented at the Experimental Biology Annual Meeting in Boston the finding that a diet rich in methionine can increase the risk of memory loss. Methionine is an essential amino acid important for several cellular functions…
News
BACE1 Inhibitors in Phase 3 Trials for Alzheimer’s are Safe in Moderate Doses, According to Study
Decreasing aggregates of amyloid beta peptide (Aβ) is the most common strategy for treating Alzheimer’s disease. One treatment that is undergoing phase 3 clinical trials is beta site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors, which are predicted to decrease the production of Aβ and prevent neurotoxic fibril and…
Researchers at Yale University School of Medicine in New Haven recently published in the journal Annals of Neurology the finding that a specific experimental anti-cancer drug can be used as an effective therapy for Alzheimer’s disease. The study is entitled “Fyn inhibition…
News
Alzheimer’s Association Reports Lack of Disclosure on Disease Diagnosis by Healthcare Providers
The diagnosis of Alzheimer’s disease is vital for patients to plan their future, access proper healthcare services and make informed decisions regarding treatment options. However, the Alzheimer’s Association recently revealed in its 2015 Alzheimer’s Disease Facts and Figures that many individuals are being deprived from an accurate diagnosis.
The United States Senate Special Committee on Aging recently hosted a meeting entitled “The Fight Against Alzheimer’s Disease: Are We on Track to a Treatment by 2025?” The meeting featured the personal testimonies of Dr.Ronald Petersen from the Mayo Clinic, a top Alzheimer’s researcher and former member of the national Alzheimer’s Association; B. Smith,…
Currently incurable, Alzheimer’s disease (AD) is projected by the Centers for Disease Control to afflict some 13.8 million people in the U.S. by 2050 if effective new treatments are not discovered. Already, millions of U.S. residents are living with severe, disabling, and progressively degenerative Alzheimer’s-related dementia. Dr. Thomas…
Amarantus BioSciences Holdings, Inc., a biotechnology firm advancing diagnostic and therapeutic products for orphan diseases in the areas of neurology, ophthalmology, psychiatry and regenerative medicine, recently announced that Mr. Gerald E. Commissiong, CEO and President, will be presenting at the Neurotech Investing and Partnering Conference being held at the Hotel Nikko…
Recent Posts
- FDA approves Auvelity to treat Alzheimer’s-related agitation May 4, 2026
- Daily Alzheimer’s pill slows brain shrinkage, boosts cognition April 6, 2026
- Researchers explore surgical treatment’s potential in Alzheimer’s March 2, 2026
- FDA fast-tracks expanded home injections for Alzheimer’s drug Leqembi February 2, 2026
- FDA decision on AXS-05 for Alzheimer’s agitation expected April 30 January 6, 2026